Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet refractoriness and alloimmunization

S J Slichter1

  • 1University of Washington School of Medicine, Seattle 98104-1256, USA.

Leukemia
|October 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.

Vox sanguinis·2016
Same author

Further studies to evaluate methods of leucoreduction to prevent alloimmune platelet refractoriness and induce tolerance in a dog platelet transfusion model.

Vox sanguinis·2016
Same author

Extended storage of autologous apheresis platelets in plasma.

Vox sanguinis·2013
Same author

Platelet transfusion: future directions.

Vox sanguinis·2004
Same author

Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.

Blood·2001
Same author

Universal WBC reduction.

Transfusion·2000

Leukocyte reduction and ultraviolet B (UVB) irradiation effectively prevent alloimmune platelet refractoriness. Modified blood products significantly reduce alloantibody production compared to standard products.

Area of Science:

  • Transfusion Medicine
  • Immunology
  • Hematology

Background:

  • Alloimmunization is a significant complication of blood transfusions.
  • Leukocyte reduction and ultraviolet B (UVB) irradiation are key methods to modify blood products.
  • Preventing alloantibody production is crucial for patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of modified blood products in preventing alloimmunization.
  • To compare leukocyte-reduced and UVB-irradiated blood components against standard products.
  • To assess the impact of apheresis-derived platelets.

Main Methods:

  • Prospective, randomized transfusion trials were conducted.
  • Patients received either unmodified, leukocyte-reduced, or UVB-irradiated platelet concentrates.

Related Experiment Videos

  • The Trial to Reduce Alloimmunization to Platelets (TRAP trial) involved 530 patients undergoing chemotherapy for acute myeloid leukemia.

    • Main Results:

    • Leukocyte-reduced and UVB-irradiated blood components significantly decreased alloantibody production.
    • Modified platelet components showed lower rates of alloimmune platelet refractoriness and lymphocytotoxic antibodies.
    • No significant differences were observed among the three types of modified platelet components.

    Conclusions:

    • Leukocyte-reduced and UVB-irradiated platelet components are equally effective in preventing alloimmune-mediated platelet refractoriness.
    • Apheresis-derived platelets offered no additional benefit over other modified components.
    • Leukocyte reduction to <5 x 10(6) may be necessary to prevent alloantibody production.